Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease

This clinical case series describes our experience with the use of Janus kinase 1/2 inhibitor baricitinib in two patients suffering from refractory adult-onset Still’s disease (AOSD) as well as in one case suffering from AOSD-like autoinflammatory disease in the context of myelodysplastic syndrome....

Descripción completa

Detalles Bibliográficos
Autores principales: Kacar, Mark, Fitton, John, Gough, Andrew K, Buch, Maya H, McGonagle, Dennis G, Savic, Sinisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Autoinflammatory Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425191/
https://www.ncbi.nlm.nih.gov/pubmed/32669454
http://dx.doi.org/10.1136/rmdopen-2020-001246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425191/
https://www.ncbi.nlm.nih.gov/pubmed/32669454
http://dx.doi.org/10.1136/rmdopen-2020-001246

Ejemplares similares